Oncolytics Biotech announced a Type C meeting with the FDA on April 16, 2026, to discuss a potential single-arm pivotal study for pelareorep combined with a checkpoint inhibitor in second-line and later treatment of squamous cell anal carcinoma (SCAC). The study aims to enroll 60-70 patients with objective response rate as the primary endpoint to support full approval. Pelareorep has shown promising results with a 30% response rate and durable effects compared to current treatments. This meeting is a key step toward regulatory approval in a cancer type with limited treatment options and poor outcomes after first-line therapy.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Data I/O Corporation announced it will release its financial results for the second quarter ending June 30, 2026, on July 30 after market close. The company will host a conference call at 2 p.m. PT/5 p.m. ET to discuss the results, accessible via pho...
